Trial Profile
A Phase I Open-Label, Dose Escalation Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Patients With Optic Nerve Atrophy (Stratum I) and Acute Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) (Stratum II)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 20 Nov 2017
Price :
$35
*
At a glance
- Drugs QPI 1007 (Primary)
- Indications Optic atrophy; Optic nerve disorders
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Quark Pharmaceuticals
- 13 Nov 2017 According Quark Pharmaceuticals media release,study conducted at 16 centers in the USA and five centers in Israel.
- 18 Aug 2014 New trial record